AZ sheds Nexium, Vimovo rights to Gruenenthal
AstraZeneca is continuing to shed products outside the scope of its three core therapy areas with the sale of certain rights to Nexium and Vimovo to Grünenthal.
Read More
Tag: Vimovo
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
